NCT04073615 is a Phase 1 clinical trial of Rivoceranib in Metastatic Colorectal Cancer, sponsored by Elevar Therapeutics.

Who is sponsoring NCT04073615?

NCT04073615 is sponsored by Elevar Therapeutics.

What drugs are being tested in NCT04073615?

Interventions in NCT04073615: Rivoceranib, Trifluridine/Tipiracil.

What condition does NCT04073615 study?

NCT04073615 studies Metastatic Colorectal Cancer.

Is NCT04073615 still recruiting?

NCT04073615 is currently terminated. Last updated 2 May 2024.

Last reviewed 2024-05-02 · How we verify

NCT04073615

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study of Rivoceranib and Trifluridine/Tipiracil for Metastatic Colorectal Cancer (mCRC)

Terminated Phase 1 Last updated 2 May 2024

What this trial tests

Phase 1 trial testing Rivoceranib in Metastatic Colorectal Cancer in 29 participants. Terminated before completion.

Timeline

18 November 2019

Primary endpoint
31 May 2023

31 May 2023

Quick facts

Lead sponsor	Elevar Therapeutics
Phase	Phase 1
Status	Terminated
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	29
Start date	18 November 2019
Primary completion	31 May 2023
Estimated completion	31 May 2023
Sites	4 locations across United States

Drugs / interventions tested

Rivoceranib (Apatinib) — full drug profile →
Trifluridine/Tipiracil

Conditions studied

Metastatic Colorectal Cancer — all drugs for Metastatic Colorectal Cancer →

Sponsor

Elevar Therapeutics — full company profile →

Who can join

18 and older, any sex, with Metastatic Colorectal Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to determine the recommended Phase 2 dose (RP2D) of rivoceranib when used in combination with trifluridine/tipiracil in participants with mCRC and to assess progression-free survival (PFS) in participants with mCRC.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Up-and-Coming Experimental Drug Options for Metastatic Colorectal Cancer.
Cimino SK, Eng C. · · 2020 · cited 5× · PMID 33204182 · DOI 10.2147/jep.s259287
Efficacy and Safety of Trifluridine/Tipiracil-Containing Combinations in Colorectal Cancer and Other Advanced Solid Tumors: A Systematic Review.
Shitara K, Falcone A, Fakih MG, George B, et al · · 2024 · cited 3× · PMID 38366864 · DOI 10.1093/oncolo/oyae007

Verify or expand the search:

Other trials of Rivoceranib

Trials testing the same drug.

NCT07147101 — Different First-line Immunotherapy for Advancer Hepatocellular Carcinoma: A Prospective Observational Study on Efficacy · not yet recruiting
NCT06308575 — A Phase II Study of Rivoceranib for Patients With Recurrent or Metastatic Olfactory Neuroblastoma · Phase 2 · withdrawn
NCT06200233 — Rivoceranib in Patients With Metastatic Thymic Epithelial Tumor · Phase 2 · not yet recruiting
NCT05287360 — A Study Comparing Four Different Rivoceranib Tablets in Healthy Participants · Phase 1 · completed
NCT04985136 — A Study of Camrelizumab Combined With Rivoceranib Mesylate Versus Investigator's Choice of Regimen in Treatment of Patie · Phase 3 · terminated

Other recruiting trials for Metastatic Colorectal Cancer

Currently open trials in the same condition.

NCT07416552 — A Study to Investigate CEA-PRIT 2.0 in Participants With Metastatic Colorectal Cancer (mCRC) · Phase 1 · recruiting
NCT07314294 — Phase II Study of EMB-01 in Recurrent/Metastatic Colorectal Cancer Patients · Phase 2 · recruiting
NCT06856837 — - IKF/AIO-QUINTIS - Evaluating Fruquintinib in Combination With Tislelizumab in Microsatellite Stable / Proficient Misma · Phase 2 · recruiting
NCT06959550 — Phase II Study of Anti-PD-1/VEGF Bispecific Antibody Ivonescimab in Patients With Previously Treated Metastatic Colorect · Phase 2 · recruiting
NCT06808685 — Real World Multicenter National Study to Evaluate the Effectiveness and Safety of Biosimilar Bevacizumab Elovie · recruiting

Other Elevar Therapeutics trials

Trials by the same sponsor.

NCT05287360 — A Study Comparing Four Different Rivoceranib Tablets in Healthy Participants · Phase 1 · completed
NCT04526106 — REFOCUS: A First-in-Human Study of Highly Selective FGFR2 Inhibitor, RLY-4008, in Patients With ICC and Other Advanced S · Phase 1, PHASE2 · completed
NCT04119453 — A Study to Evaluate the Efficacy and Safety of Rivoceranib in Participants With Recurrent or Metastatic Adenoid Cystic C · Phase 2 · terminated
NCT03707028 — A Study to Evaluate Safety, Tolerability, and Efficacy Profile of Rivoceranib With Paclitaxel in Advanced Gastric or Gas · Phase 1, PHASE2 · terminated
NCT03396211 — A Study to Evaluate Apatinib (Also Known as Rivoceranib) Plus Nivolumab in Participants With Unresectable or Metastatic · Phase 1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04073615 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Elevar Therapeutics
Last refreshed: 2 May 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04073615.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing